Mawer Investment Management Ltd. Sells 10,313 Shares of Abbott Laboratories $ABT

Mawer Investment Management Ltd. reduced its position in shares of Abbott Laboratories (NYSE:ABT) by 0.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,245,467 shares of the healthcare product maker’s stock after selling 10,313 shares during the quarter. Mawer Investment Management Ltd. owned 0.07% of Abbott Laboratories worth $156,045,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. MidAtlantic Capital Management Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $25,000. Harbor Capital Advisors Inc. purchased a new position in shares of Abbott Laboratories in the fourth quarter worth approximately $27,000. Guerra Advisors Inc purchased a new position in Abbott Laboratories during the third quarter valued at approximately $31,000. Bridge Generations Wealth Management LLC purchased a new position in Abbott Laboratories during the third quarter valued at approximately $33,000. Finally, Leonteq Securities AG purchased a new position in Abbott Laboratories during the fourth quarter valued at approximately $35,000. 75.18% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Abbott Laboratories

In other news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction on Monday, April 27th. The shares were acquired at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the completion of the transaction, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. The trade was a 0.15% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Philip P. Boudreau acquired 2,200 shares of the business’s stock in a transaction on Thursday, April 23rd. The shares were purchased at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer directly owned 2,200 shares of the company’s stock, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders own 0.46% of the company’s stock.

Wall Street Analyst Weigh In

ABT has been the topic of several analyst reports. The Goldman Sachs Group lowered their price target on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. Mizuho reduced their price objective on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Evercore reduced their price objective on shares of Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. JPMorgan Chase & Co. reduced their price objective on shares of Abbott Laboratories from $123.00 to $110.00 and set an “overweight” rating on the stock in a research report on Friday, April 17th. Finally, Raymond James Financial reduced their price objective on shares of Abbott Laboratories from $130.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, Abbott Laboratories currently has an average rating of “Moderate Buy” and a consensus target price of $119.09.

Abbott Laboratories Trading Up 2.5%

Shares of ABT opened at $87.70 on Tuesday. The company’s fifty day moving average is $94.07 and its 200 day moving average is $110.31. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $139.06. The stock has a market capitalization of $152.75 billion, a PE ratio of 24.57, a P/E/G ratio of 1.43 and a beta of 0.63. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The company had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. During the same quarter in the previous year, the business posted $1.09 earnings per share. Abbott Laboratories’s quarterly revenue was up 7.8% on a year-over-year basis. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Sell-side analysts expect that Abbott Laboratories will post 5.48 earnings per share for the current fiscal year.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.